Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2024

Pharma News, 2024

Pfizer meets Phase III primary endpoints for RSV vaccine Abrysvo
Pfizer meets Phase III primary endpoints for RSV vaccine Abrysvo
Pfizer intends to submit data from MONeT to regulatory agencies in a bid to expand the vaccine’s indicated treatment population.
European lab services company buys Ascend Clinical LLC
European lab services company buys Ascend Clinical LLC
Eurofins Scientific has purchased the largest independent dialysis testing lab in the United States. Terms of the acquisition were not disclosed.
Acorda inks $185M asset sale to Merz, files for bankruptcy after years of disappointing sales
Acorda inks $185M asset sale to Merz, files for bankruptcy after years of disappointing sales
After years of struggling with hurdles such as generic competition and significantly lower-than-expected sales of its top meds, Acorda Therapeutics is hanging up the gloves with a $185 million deal to...
Targeting RAS proteins may prevent relapse in Acute Myeloid Leukemia
Targeting RAS proteins may prevent relapse in Acute Myeloid Leukemia
Targeting RAS family proteins in FLT3-ITD+ Acute Myeloid Leukemia shuts off a common route to drug resistance. Relapses in a common form of leukemia may be preventable following new research which...
J&J and Legend’s Carvykti scores early line approval for MM by FDA
J&J and Legend’s Carvykti scores early line approval for MM by FDA
J&J and Legend’s CAR-T cell therapy has been approved as a second-line therapy for patients with multiple myeloma. J&J and Legend Biotech’s Carvykti is a B-cell maturation antigen (BCMA) d...
FDA accepts Shorla’s oral liquid leukaemia drug NDA
FDA accepts Shorla’s oral liquid leukaemia drug NDA
A new drug application (NDA) from US-Ireland speciality pharmaceutical company Shorla Oncology has been accepted by the US Food and Drug Administration (FDA) for SH-201, an oral versio...
Acumen and Lonza to produce Alzheimer’s drug sabirnetug
Acumen and Lonza to produce Alzheimer’s drug sabirnetug
Acumen Pharmaceuticals has entered a strategic partnership with Swiss contract manufacturer Lonza to further the development of sabirnetug (ACU193), a potential treatment for Alzheimer’s dis...
Amylyx axes ALS drug from market after Phase III failure
Amylyx axes ALS drug from market after Phase III failure
Last month, Amylyx announced that the Phase III confirmatory trial of ALS drug Relyvrio failed to meet its primary and secondary endpoints.
GSK expands Asia-Pacific reach for Trelegy Ellipta with Singapore approval
GSK expands Asia-Pacific reach for Trelegy Ellipta with Singapore approval
GSK’s Trelegy Ellipta has been approved as a maintenance therapy for both asthma and COPD in Singapore. Trelegy Ellipta is approved as a maintenance treatment for COPD and asthma in the US.
As Humira biosim sales languish, Boehringer Ingelheim plots layoffs in pivot to hybrid marketing model
As Humira biosim sales languish, Boehringer Ingelheim plots layoffs in pivot to hybrid marketing model
Over the past year, nine Humira biosimilars have leapt onto the U.S. market, including Boehringer's Cyltezo.  
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced topline resul...
FDA approves Abecma as ‘earlier line of therapy’ for triple-class exposed multiple myeloma
FDA approves Abecma as ‘earlier line of therapy’ for triple-class exposed multiple myeloma
The FDA has approved Bristol Myers Squibb and 2seventy bio’s idecabtagene vicleucel for treatment of patients with triple-class exposed relapsed or refractory multiple myeloma, according to a compan...
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand